Serum testosterone and prostate cancer in men with germline <i>BRCA1/2</i> pathogenic variants.

ABSTRACT:

Objectives

The relation of serum androgens and the development of prostate cancer (PCa) is subject of debate. Lower total testosterone (TT) levels have been associated with increased PCa detection and worse pathological features after treatment. However, data from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) and Prostate Cancer Prevention (PCPT) trial groups indicate no association. The aim of this study is to investigate the association of serum androgen levels and PCa detection in a prospective screening study of men at higher genetic risk of aggressive PCa due to BRCA1/2 pathogenic variants (PVs), the IMPACT study.

Methods

Men enrolled in the IMPACT study provided serum samples during regular visits. Hormonal levels were calculated using immunoas

SUBMITTER: Dias A 

PROVIDER: S-EPMC10071088 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature